• Something wrong with this record ?

Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study

G. Würthwein, C. Lanvers-Kaminsky, J. Gerss, A. Möricke, M. Zimmermann, J. Stary, P. Smisek, A. Attarbaschi, C. Nath, M. Zucchetti, C. Rizzari, M. Schrappe, J. Boos, AIEOP-BFM ALL 2009 Asparaginase Working Party

. 2020 ; 42 (3) : 435-444. [pub] -

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21020535

BACKGROUND: Therapeutic drug monitoring (TDM) can identify patients with subtherapeutic asparaginase (ASNase) activity [silent inactivation (SI)] and prospectively guide therapeutic adaptation. However, limited intra-individual variability is a precondition for targeted dosing and the diagnosis of SI. METHODS: In the AIEOP-BFM acute lymphoblastic leukemia (ALL) 2009 trial, 2771 children with ALL were included and underwent ASNase-TDM in a central laboratory in Münster. Two biweekly administrations of pegylated ASNase during induction and a third dose during reinduction or the high-risk block, which was administered several weeks later, were monitored. We calculated (1) the incidence of SI; and (2) the predictivity of SI for SI after the subsequent administration. ASNase activities monitored during induction were categorized into percentiles at the respective sampling time points. These percentiles were used to calculate the intra-individual range of percentiles as a surrogate for intrapatient variability and to evaluate the predictivity of ASNase activity for the subsequent administration. RESULTS: The overall incidence of SI was low (4.9%). The positive predictive value of SI identified by one sample was ≤21%. Confirmation of SI by a second sample indicated a high positive predictive value of 100% for biweekly administrations, but not for administration more than 17 weeks later. Sampling and/or documentation errors were risks for misdiagnosis of SI. High intra-individual variability in ASNase activities, with ranges of percentiles over more than 2 quartiles and low predictivity, was observed in approximately 25% of the patients. These patients were likely to fail dose individualization based on TDM data. CONCLUSIONS: To use TDM as a basis for clinical decisions, standardized clinical procedures are required and high intra-individual variability should be taken into account. Details of the treatment are available in the European Clinical Trials Database at https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004270-43/DE.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020535
003      
CZ-PrNML
005      
20210830102159.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/FTD.0000000000000727 $2 doi
035    __
$a (PubMed)32022785
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Würthwein, Gudrun $u Department of Pediatric Hematology and Oncology, University Children's Hospital of Münster, Münster, Germany
245    10
$a Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study / $c G. Würthwein, C. Lanvers-Kaminsky, J. Gerss, A. Möricke, M. Zimmermann, J. Stary, P. Smisek, A. Attarbaschi, C. Nath, M. Zucchetti, C. Rizzari, M. Schrappe, J. Boos, AIEOP-BFM ALL 2009 Asparaginase Working Party
520    9_
$a BACKGROUND: Therapeutic drug monitoring (TDM) can identify patients with subtherapeutic asparaginase (ASNase) activity [silent inactivation (SI)] and prospectively guide therapeutic adaptation. However, limited intra-individual variability is a precondition for targeted dosing and the diagnosis of SI. METHODS: In the AIEOP-BFM acute lymphoblastic leukemia (ALL) 2009 trial, 2771 children with ALL were included and underwent ASNase-TDM in a central laboratory in Münster. Two biweekly administrations of pegylated ASNase during induction and a third dose during reinduction or the high-risk block, which was administered several weeks later, were monitored. We calculated (1) the incidence of SI; and (2) the predictivity of SI for SI after the subsequent administration. ASNase activities monitored during induction were categorized into percentiles at the respective sampling time points. These percentiles were used to calculate the intra-individual range of percentiles as a surrogate for intrapatient variability and to evaluate the predictivity of ASNase activity for the subsequent administration. RESULTS: The overall incidence of SI was low (4.9%). The positive predictive value of SI identified by one sample was ≤21%. Confirmation of SI by a second sample indicated a high positive predictive value of 100% for biweekly administrations, but not for administration more than 17 weeks later. Sampling and/or documentation errors were risks for misdiagnosis of SI. High intra-individual variability in ASNase activities, with ranges of percentiles over more than 2 quartiles and low predictivity, was observed in approximately 25% of the patients. These patients were likely to fail dose individualization based on TDM data. CONCLUSIONS: To use TDM as a basis for clinical decisions, standardized clinical procedures are required and high intra-individual variability should be taken into account. Details of the treatment are available in the European Clinical Trials Database at https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004270-43/DE.
650    _2
$a mladiství $7 D000293
650    _2
$a asparaginasa $x aplikace a dávkování $x krev $x terapeutické užití $7 D001215
650    _2
$a asparagin $x krev $7 D001216
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a monitorování léčiv $x metody $7 D016903
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a metabolická inaktivace $x fyziologie $7 D008658
650    _2
$a kojenec $7 D007223
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a polyethylenglykoly $x aplikace a dávkování $x terapeutické užití $7 D011092
650    _2
$a akutní lymfatická leukemie $x farmakoterapie $7 D054198
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lanvers-Kaminsky, Claudia $u Department of Pediatric Hematology and Oncology, University Children's Hospital of Münster, Münster, Germany
700    1_
$a Gerss, Joachim $u Institute of Biostatistics and Clinical Research, University Münster, Münster, Germany
700    1_
$a Möricke, Anja $u Department of General Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
700    1_
$a Zimmermann, Martin $u Department of Pediatric Hematology and Oncology, Hannover Medical School, Germany
700    1_
$a Stary, Jan $u Department of Pediatric Hematology and Oncology, Charles University and University Hospital, Motol, Prague, Czech Republic
700    1_
$a Smisek, Petr $u Department of Pediatric Hematology and Oncology, Charles University and University Hospital, Motol, Prague, Czech Republic
700    1_
$a Attarbaschi, Andishe $u Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
700    1_
$a Nath, Christa $u Departments of Biochemistry and Oncology, The Children's Hospital at Westmead, Faculty of Pharmacy, University of Sydney, Sydney, Australia
700    1_
$a Zucchetti, Massimo $u Department of Oncology, Laboratory of Cancer Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy; and
700    1_
$a Rizzari, Carmelo $u Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
700    1_
$a Schrappe, Martin $u Department of General Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
700    1_
$a Boos, Joachim $u Department of Pediatric Hematology and Oncology, University Children's Hospital of Münster, Münster, Germany
710    2_
$a AIEOP-BFM ALL 2009 Asparaginase Working Party
773    0_
$w MED00004503 $t Therapeutic drug monitoring $x 1536-3694 $g Roč. 42, č. 3 (2020), s. 435-444
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32022785 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102159 $b ABA008
999    __
$a ok $b bmc $g 1691163 $s 1140981
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 42 $c 3 $d 435-444 $e - $i 1536-3694 $m Therapeutic drug monitoring $n Ther Drug Monit $x MED00004503
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options